Skip to main content

Dicerna Pharmaceuticals, Inc. (DRNA)

NASDAQ: DRNA · IEX Real-Time Price · USD
21.50
+0.27 (1.27%)
After-hours:Oct 15, 2021 6:39 PM EDT
21.23
-0.07 (-0.33%)
At close: Oct 15, 4:00 PM
Market Cap1.65B
Revenue (ttm)178.77M
Net Income (ttm)-129.22M
Shares Out77.03M
EPS (ttm)-1.71
PE Ration/a
Forward PE28.49
Dividendn/a
Ex-Dividend Daten/a
Volume465,116
Open21.50
Previous Close21.30
Day's Range20.83 - 21.50
52-Week Range18.54 - 40.14
Beta1.09
AnalystsStrong Buy
Price Target30.89 (+45.5%)
Est. Earnings DateNov 4, 2021

About DRNA

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercializing of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare, cardiometabolic, viral, and chronic liver diseases; complement-mediated diseases; and neurodegenerative diseases and pain. Its principal development programs include nedosiran for the treatment of primary hyperoxaluria; RG6346 for the...

IndustryBiotechnology
IPO DateJan 30, 2014
CEODouglas Fambrough
Employees302
Stock ExchangeNASDAQ
Ticker SymbolDRNA
Full Company Profile

Financial Performance

In 2020, DRNA's revenue was $164.31 million, an increase of 587.36% compared to the previous year's $23.90 million. Losses were -$112.75 million, -6.40% less than in 2019.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for DRNA stock is "Strong Buy." The 12-month stock price forecast is 30.89, which is an increase of 45.50% from the latest price.

Price Target
$30.89
(45.50% upside)
Analyst Consensus: Strong Buy

News

Dicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced an abstract on clinical data from the PHYOX™2 trial of nedosiran has been accepted as a late-breaker poster presentation at ASN.

14 hours ago - Business Wire

Dicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meet...

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that two abstracts related to the Company's clinical development programs have been accepted for poster presentations at AASLD.

1 day ago - Business Wire

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options for one new employee

2 weeks ago - Business Wire

Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for th...

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that it dosed the first subjects in its Phase 1 clinical trial to assess DCR-AUD.

2 weeks ago - Business Wire

Dicerna Announces New Executive Leadership Appointments

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today announced new executive leadership appointments.

3 weeks ago - Business Wire

Dicerna to Participate in 16th Annual Citi Biopharma Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, to...

1 month ago - Business Wire

Wednesday Afternoon Analyst Upgrades and Downgrades: BioNTech, United Airlines, Workhorse and More

With the trading day almost halfway over, the S&P 500 and Dow Jones industrial average hit even more record highs in Wednesday's session.

Other symbols:BNTXUALWKHSLTHMLUVUWW
2 months ago - 24/7 Wall Street

Dicerna Pharmaceuticals (DRNA) Reports Q2 Loss, Misses Revenue Estimates

Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -203.92% and -68.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Dicerna Pharmaceuticals: Q2 Earnings Insights

Shares of Dicerna Pharmaceuticals (NASDAQ:DRNA) fell 0.2% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were down 23.26% year over year to ($0.53), wh...

2 months ago - Benzinga

Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna today reported its financial results for the second quarter ended June 30, 2021 and provided a corporate update.

2 months ago - Business Wire

Why Dicerna Pharmaceuticals Stock Is Tumbling on Friday

A less than satisfying result from a phase 2 trial with nedosiran makes the company's future difficult to predict.

2 months ago - The Motley Fool

Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Prima...

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced positive top-line results from its PHYOX™2 pivotal clinical trial of nedosiran, which is in development for as a treatment for PH.

2 months ago - Business Wire

Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that the Company will release its second quarter 2021 financial results before market open on Monday, Aug. 9, 2021.

2 months ago - Business Wire

Dicerna Pharmaceuticals (DRNA) to Report Q2 Results: Wall Street Expects Earnings Growth

Dicerna Pharmaceuticals (DRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcoho...

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced the FDA clearance of its IND application for DCR-AUD for the treatment of alcohol use disorder.

2 months ago - Business Wire

Dicerna Posts Updated Data From Belcesiran Early-Stage Study For Genetic Liver Disease

Dicerna Pharmaceuticals Inc (NASDAQ: DRNA) has announced interim results from the four completed active-treatment dose cohorts (0.1, 1.0, 3.0, and 6.0 mg/kg) of its Phase 1 trial of belcesiran. The GalX...

2 months ago - Benzinga

Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-As...

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced interim results from its Phase 1 trial of belcesiran for treatment of alpha-1 antitrypsin deficiency-associated liver disease.

2 months ago - Business Wire

New Strong Sell Stocks for July 20th

AEVA, BIDU, CBAY, DRNA and RACE have been added to the Zacks Rank #5 (Strong Sell) List on July 20, 2021.

Other symbols:AEVABIDUCBAYRACE
2 months ago - Zacks Investment Research

New Strong Sell Stocks for July 15th

ATEC, DRNA, AG, PAX, and AUPH have been added to the Zacks Rank #5 (Strong Sell) List on July 15, 2021

Other symbols:AGATECAUPHPAX
3 months ago - Zacks Investment Research

Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options for one new employee

3 months ago - Business Wire

Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitr...

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced it has initiated patient dosing in its Phase 2 ESTRELLA trial of belcesiran, which is in development for the treatment of AATLD.

3 months ago - Business Wire

Dicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced it has completed dosing in the Company's PHYOX™4 clinical trial, evaluating nedosiran for the treatment of patients with PH3.

3 months ago - Business Wire

2 Biotech Stocks ARK Invest Bought in June

Should you follow Cathie Wood's latest genomic revolution investments?

Other symbols:RPTX
4 months ago - The Motley Fool

Dicerna to Participate in 42nd Annual Goldman Sachs Global Healthcare Conference

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced that Doug Fambrough will participate in a virtual fireside chat at the 42nd Annual Goldman Sachs Global Healthcare Conference.

4 months ago - Business Wire

Dicerna Announces FDA Acceptance of Lilly's Investigational New Drug (IND) Application for LY3819469

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna announced the U.S. FDA's acceptance of the Investigational New Drug (IND) application filed by Lilly for LY3819469.

4 months ago - Business Wire